The near-infrared fluorescence imaging system is an innovative technology that can help surgeons to easily and safely perform video-assisted thoracoscopic thoracic duct ligation for the treatment of chylothorax.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thoracic
November 28, 2023
November 22, 2023
This video describes the technique and approach to the steps of the repair of the left mainstem bronchus during a robotic-assisted tracheobronchoplasty.
November 20, 2023
Lung cancer screening with low-dose CT is being introduced in several European countries. The management of incidental findings, both pulmonary and extrapulmonary, is an important component of the clinical and cost effectiveness of screening programs. A multi-society European group was convened to discuss the issue.
November 20, 2023
A unique approach via the right chest for robotic resection of a mediastinal ectopic parathyroid adenoma with indocyanine green localization.
November 16, 2023
Joel discusses the latest news in CT surgery and clinical videos on CTSNet.
November 16, 2023
This paper looks to explore the outcomes in obese patients with non-small cell lung cancer following VATS or open lobectomy. The authors utilized data from the European Society of Thoracic Surgeons Database to assess morbidity and postoperative length of stay in 78,018 patients across a fourteen-year period.
November 15, 2023
This video illustrates the use of a robotic platform for the resection of an esophageal lesion and minimally invasive suture.
November 13, 2023
This is a video of an operation with the ArtiSential wristed instruments in VATS surgery.
November 10, 2023
Joel discusses the latest CT surgery news and content on CTSNet.
November 9, 2023
This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received Durvalumab and the remaining 402 a placebo. The two primary endpoints measured were event-free survival and pathological complete resection.